文献速递妇科

MAPK-ERK1/2信号反馈激活导致子宫内膜癌对T-DXd耐药

Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.
PubMed 文献 · Gynecol Oncol · 2026-08-13

本研究利用四种子宫内膜癌细胞系、患者来源类器官及HEC-1B异种移植模型,探讨T-DXd耐药机制。发现T-DXd处理增加ERK1/2激活并降低HER2表达,联合MEK1/2抑制剂trametinib可恢复HER2表达并显著抑制细胞和类器官生长。T-DXd还增加DNA损伤和细胞周期相关蛋白磷酸化(包括ATR),ERK1/2激活ATR导致G2/M期阻滞。

要点

  • T-DXd处理激活ERK1/2并降低HER2表达,参与耐药
  • 联合trametinib可恢复HER2表达并增强抗肿瘤效果
  • ERK1/2激活ATR导致G2/M期阻滞

核心结论

  • T-DXd激活ERK1/2和ATR导致耐药,联合MEK1/2抑制剂可增强疗效。

研究设计与样本

  • 使用四种子宫内膜癌细胞系(KLE、HEC-1B、Ishikawa、AN3 CA)及患者来源类器官。
  • 采用Bliss协同模型评估药物相互作用,免疫印迹和磷酸化蛋白质组学分析信号通路。
  • 体内疗效采用HEC-1B异种移植模型,给予T-DXd和trametinib单药或联合。

主要发现

  • T-DXd处理增加ERK1/2激活并降低HER2表达。
  • 联合trametinib恢复HER2表达并显著抑制细胞系(体外和体内)及类器官生长。
  • T-DXd增加DNA损伤和细胞周期相关蛋白磷酸化,包括ATR;ERK1/2激活ATR导致G2/M期阻滞。

临床怎么用

  • 对于子宫内膜癌,T-DXd联合MEK1/2抑制剂可能克服耐药,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify targetable pathways that can overcome resistance to trastuzumab deruxtecan (T-DXd) in endometrial cancer. METHODS: We used four endometrial cancer cell lines with different genetic backgrounds (KLE, HEC-1B, Ishikawa, and AN3 CA). Patient-derived endometrial organoids were established from surgically resected tumors and maintained in basement membrane extract with optimized media. Drug interactions were evaluated using Bliss synergy modeling. Organoid growth and treatment response were quantified by imaging-based size measurements. Protein signaling changes were analyzed by immunoblotting and comprehensive phosphoproteomic profiling. Cell cycle effects were assessed by flow cytometry. In vivo efficacy was evaluated using HEC-1B xenograft models treated with T-DXd and trametinib alone or in combination. Immunohistochemistry was performed on tumor and organoid samples to assess pathway activation and proliferation markers. Statistical analyses were conducted using GraphPad Prism 9, R and Python packages. RESULTS: T-DXd treatment increases ERK1/2 activation and reduces HER2 expression across various endometrial cancer cell lines. The addition of trametinib, a MEK1/2 inhibitor, to T-DXd, restores HER2 expression and markedly reduces the growth of both endometrial cancer cell lines (in vitro and in vivo), and organoids. Phosphoproteomic assays showed that T-DXd increases phosphorylation of proteins involved in DNA damage and the cell cycle, including ATR. We also found that ERK1/2 plays a key role in activating ATR and causing cell cycle arrest in the G2/M phase. CONCLUSION: T-DXd activates ERK1/2 and ATR, which contributes to resistance, and combining T-DXd with a MEK1/2 inhibitor enhances treatment response.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nguyen AQ, Bednarek N, Al-Sawalha I, et al. Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers. Gynecol Oncol. 2026. PMID: 42594534. doi:10.1016/j.ygyno.2026.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。